These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 1455003)

  • 1. Response to EPO therapy.
    Bommer J
    Przegl Lek; 1992; 49(1-2):36-7. PubMed ID: 1455003
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment with low doses of intravenous iron does not modify hemoglobin nor the erythropoietin dosage].
    Fernández-Gallego J; Martín MA; Alonso A; Toledo R
    Nefrologia; 2006; 26(1):143-4. PubMed ID: 16649439
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of anemia of chronic renal failure.
    Singh NP; Anuradha S; Chandrashekhar ; Agarwal SK
    J Assoc Physicians India; 1999 Feb; 47(2):216-23. PubMed ID: 10999096
    [No Abstract]   [Full Text] [Related]  

  • 4. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anemia in terminal kidney failure. Pathogenesis and therapy].
    Heilmann E
    Fortschr Med; 1977 Feb; 95(6):338-44. PubMed ID: 838456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of anemia in patients with chronic renal disease: is it time for self-criticism?].
    Del Vecchio L
    G Ital Nefrol; 2007; 24(4):285. PubMed ID: 17659497
    [No Abstract]   [Full Text] [Related]  

  • 7. [Individual differences in the efficacy of Recormon in patients with terminal kidney failure. The role of iron deficiency].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kondakhchan MA; Rogov VA; Trofimova EI
    Ter Arkh; 1993; 65(6):45-8. PubMed ID: 8378849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of recombinant human erythropoietin (rHu-EPO) on anemia and selected biochemical parameters in patients in the pre-dialysis period].
    Sułowicz W; Drozdz M; Hanicki Z; Kraśniak A; Kuźniewski M
    Przegl Lek; 1992; 49(1-2):50-3. PubMed ID: 1455007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of red blood cell indices (MCV, MCH, RDW) in monitoring chronic hemodialysis patients treated with recombinant erythropoietin.
    Fialon P; Leaute AG; Sassier P; Vallot C; Wone C
    Pathol Biol (Paris); 1993 Dec; 41(10):931-5. PubMed ID: 8159473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin for anaemia associated with chronic renal failure in predialysis patients.
    Schaefer RM; Schaefer L; Heidland A
    Przegl Lek; 1992; 49(1-2):41-2. PubMed ID: 1455005
    [No Abstract]   [Full Text] [Related]  

  • 12. Subcutaneous erythropoietin in the treatment of renal anaemia.
    Drinovec J; Varl J
    Przegl Lek; 1992; 49(1-2):38-40. PubMed ID: 1455004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. Multicenter Study Group, Israel.
    Yagil Y
    Isr J Med Sci; 1997 Jan; 33(1):36-44. PubMed ID: 9203516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
    Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
    Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Etiopathogenic mechanisms of anemia in hemodialysis patients].
    Marco Franco JE; Alarcón Zurita A; Dalmau Diana M; Pizá Buñola C; Morey Molina A; Bestard Palmer J; Mairata Bosch S; Ribas Mundó M
    Rev Clin Esp; 1983 Jan; 168(2):83-5. PubMed ID: 6344155
    [No Abstract]   [Full Text] [Related]  

  • 16. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW; Haley NR; Adamson JW
    Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum erythropoietin titers in the anemia of chronic renal failure and other hematological states.
    Urabe A; Saito T; Fukamachi H; Kubota M; Takaku F
    Int J Cell Cloning; 1987 May; 5(3):202-8. PubMed ID: 3598244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anemia in chronic renal insufficiency].
    Heilmann E
    Fortschr Med; 1975 Dec; 93(34):1718-20. PubMed ID: 1193526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of anemia in chronically dialyzed patients].
    Moynot A
    Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.